Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.

Lung cancer (Amsterdam, Netherlands) - 1 Apr 2022

Bauml Joshua M, Li Bob T, Velcheti Vamsidhar, Govindan Ramaswamy, Curioni-Fontecedro Alessandra, Dooms Christophe, Takahashi Toshiaki, Duda Andrew W, Odegaard Justin I, Cruz-Guilloty Fernando, Jin Liming, Zhang Ying, Anderson Abraham, Skoulidis Ferdinandos

Abstract excerpt

OBJECTIVES: Effective therapy for non-small-cell lung cancer (NSCLC) depends on morphological and genomic classification, with comprehensive screening for guideline-recommended biomarkers critical to guide treatment. Companion diagnostics, which provide robust genotyping results, represent an important component of personalized oncology. We evaluated the clinical validity of Guardant360 CDx as a companion...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Carcinoma, Non-Small-Cell Lung
Share to Clinical Trials, Phase II as Topic

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Lung Neoplasms

Share to Mutation

Share to Piperazines

Share to Proto-Oncogene Proteins p21(ras)

Share to Pyridines

Share to Pyrimidines

Source

Open in PubMed Open full text

Identifiers

PMID: 34838325
DOI: 10.1016/j.lungcan.2021.10.007
PMCID: PMC10325630

Genes

KRAS
STK11
TP53

Variants

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 4 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Clinical validation of Guardant360 CDx as a blood-based companion diagnostic for sotorasib.PMID 34838325Read ↗

KRAS G12C in advanced NSCLC: Prevalence, co-mutations, and testing.Semantic proximity Read ↗

Pan-Tumor Analytical Validation and Osimertinib Clinical Validation in EGFR Mutant Non-Small-Cell Lung Cancer, Supporting the First Next-Generation Sequencing Liquid Biopsy in Vitro Diagnostic.Semantic proximity Read ↗

Clinical Utility of Circulating Tumor DNA in Patients With Advanced KRASG12C-Mutated NSCLC Treated With Sotorasib.Semantic proximity Read ↗

KRAS G12C mutation in NSCLC in a small genetic center: insights into sotorasib therapy response potential.Semantic proximity Read ↗

Assessing In House Comprehensive Genomic Profiling by Liquid Biopsy for NSCLC PatientsSemantic proximity Read ↗

Feasibility of next-generation sequencing (Oncomine™ DX Target Test) for the screening of oncogenic mutations in advanced non-small-cell lung cancer patients.Semantic proximity Read ↗

Targeting KRASp.G12C Mutation in Advanced Non-Small Cell Lung Cancer: a New Era Has Begun.Semantic proximity Read ↗

Clinical Impact of Plasma and Tissue Next-Generation Sequencing in Advanced Non-Small Cell Lung Cancer: A Real-World Experience.Semantic proximity Read ↗

Clinical Utility of Comprehensive Genomic Profiling for Advanced Non-Small Cell Lung Cancer: A Single-Center Retrospective Study.Semantic proximity Read ↗

Identification of KRASG12C Mutations in Circulating Tumor DNA in Patients With Cancer.Semantic proximity Read ↗

Profile of the Roche cobas® EGFR mutation test v2 for non-small cell lung cancer.Semantic proximity Read ↗

Clinical Utility of Comprehensive Cell-free DNA Analysis to Identify Genomic Biomarkers in Patients with Newly Diagnosed Metastatic Non–small Cell Lung CancerSemantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.